poisar

Stocks · News reference

JP Morgan Maintains Overweight on Replimune Group, Raises Price Target to $21

BenzingaBenzinga Newsdesk

JP Morgan analyst Anupam Rama maintains Replimune Group (NASDAQ:REPL) with a Overweight and raises the price target from $20 to $21.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — Replimune Group, Inc. (REPL)

    Filed: 2026-08-14 AccNo: 0001104659-26-096483 Size: 266 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

  2. BenzingaBenzinga Newsdesk

    Replimune Group Q1 EPS $(0.72) Beats $(0.73) Estimate

    Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.73) by 1.37 percent. This is a 24.21 percent increase over losses of $(0.95) per share from